Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review

Sweiti, Hussein; Ekwunife, Obinna Ikechukwu; Jaschinski, Thomas; Lhachimi, Stefan K.

doi:10.1016/j.curtheres.2017.01.007

Cited by 45 publications

(44 citation statements)

References 78 publications

(269 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Not only does the research focus on the development of a novel drug, but the research is also conducted to identify potential repurposed therapeutic agents for the treatment of Ebola [34,35]. Toremifene and clomiphene, the selective estrogen reuptake modulators, are currently known as the drug to treat breast cancer and infertility, respectively.…”

Section: Introductionmentioning

confidence: 99%

Bioinformatics Approach to Screening and Developing Drug against Ebola

Tambunan¹,

Alkaff²,

Nasution³

2018

Advances in Ebola Control

View full text Add to dashboard Cite

Ebola is an acute disease causing hemorrhagic fever marked with high mortality rate. The patients who suffer from Ebola only receive palliative care because there is no available drug which can consistently cure this disease. To date, no cure has been found to treat this disease. Bioinformatics and computer-aided drug discovery and development (CADDD) are employed to utilize the readily available genomic and proteomic data and enhance the hit rate of the novel and repurposed drug for Ebola therapy. Additionally, the time and cost of wet laboratory experiments can be drastically reduced by the support of bioinformatics approach. Our laboratory has succeeded not only in creating the bioinformatics research pipeline but also screening and developing the drug candidate to cure Ebola. Through pharmacophore-based virtual screening and molecular docking simulations, we discovered that about three Indonesian natural product compounds have noteworthy molecular interactions against EBOV VP35 protein, which are responsible for the RNA synthesis of the Ebola. These compounds can be reevaluated further through advances in in silico simulation and in vitro experiments.

show abstract

Section: Introductionmentioning

confidence: 99%

Bioinformatics Approach to Screening and Developing Drug against Ebola

Tambunan¹,

Alkaff²,

Nasution³

2018

Advances in Ebola Control

View full text Add to dashboard Cite

show abstract

“…This is worsened by the high level of biocontainment (BSL-4) necessary for the manipulation of this virus that considerably hampers the development of antiviral drugs and vaccines. In this context, DR studies were prompted by the last outbreak (extensively reviewed in [30][31][32]). EBOV provides a unique example of a DR approach applied directly in clinical trials, as during the last outbreak several drugs were evaluated in infected patients (under both clinical trials and compassionate use) to test their ability to protect from lethal EBOV infection.…”

Section: Drug Repurposing For Rna Virus Infectionsmentioning

confidence: 99%

“…These included the viral RNA polymerase inhibitors favipiravir (approved in Japan for the treatment of influenza A virus) [31,33], GS-5734 (an adenosine analog active against highly pathogenic coronaviruses) [34,35], and amodiaquine (an antimalarial drug widely used in Africa). Treatment of EBOV-infected patients with these drugs has been associated with a decrease in fatality rate compared to control patients [30]; however, their efficacy remains to be confirmed in randomized clinical studies. Preclinical DR studies were also performed with both live viruses and pseudoviruses and led to the identification of a series of approved drugs able to confer protection from lethal EBOV infection in animal models.…”

Section: Drug Repurposing For Rna Virus Infectionsmentioning

confidence: 99%

Drug Repurposing for Viral Infectious Diseases: How Far Are We?

Mercorelli

Palù

Loregian

2018

Trends in Microbiology

221

188

View full text Add to dashboard Cite

Despite the recent advances in controlling some viral pathogens, most viral infections still lack specific treatment. Indeed, the need for effective therapeutic strategies to combat 'old', emergent, and re-emergent viruses is not paralleled by the approval of new antivirals. In the past years, drug repurposing combined with innovative approaches for drug validation, and with appropriate animal models, significantly contributed to the identification of new antiviral molecules and targets for therapeutic intervention. In this review, we describe the main strategies of drug repurposing in antiviral discovery, discuss the most promising candidates that could be repurposed to treat viral infections, and analyze the possible caveats of this trendy strategy of drug discovery.

show abstract

“…The study of favipiravir against Ebola virus has shown good results both in vitro and in vivo. 15 The ability of Chloroquine to inhibit the Ebola virus has shown promising outcomes in different in vitro studies with various cell lines. 16 Toremiphene and clomiphene are widely available selective estrogen reuptake modulators approved for the treatment of breast cancer and infertility, respectively.…”

Section: Repurposing In Ebola Virus Infectionmentioning

confidence: 99%

Drug Repurposing in Antiviral Research: A Current Scenario

Mani¹,

Wadhwani²,

Krishnamurthy³

2019

JYP

View full text Add to dashboard Cite

Better understand the unexplored parts of the drugs you know than the drugs unidentified. Drug repurposing is a promising, fast and cost-effective method that can overcome traditional de novo drug discovery and development challenges of targeting various diseases and disorders. Drug repurposing, the process of identifying new uses for the existing or candidate drugs is an effective strategy for drug discovery in various diseases. Identifying new drugs and new target is significant in today's world with a new disease emerging every day. With increase in number of the emerging viral infections day by day, the targeted therapies for those are not discovered in parallel. The drug repurposing approach has given many promising drug candidates for various viral infectious diseases like Ebola, ZIKA, dengue, influenza, HIV, HSV, CMV infections and various other infectious diseases. The emergence of resistance to existing antiviral drugs and re-emerging viral infections are the biggest challenges in the antiviral drug discovery. The drug repurposing approach is an assuring strategy in finding new potential antiviral agents within a short span of time to overcome the challenges in antiviral therapy. In this review, we describe the most promising results of the drug repurposing approach in the treatment of various infectious diseases.This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

show abstract

Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review

Cited by 45 publications

References 78 publications

Bioinformatics Approach to Screening and Developing Drug against Ebola

Bioinformatics Approach to Screening and Developing Drug against Ebola

Drug Repurposing for Viral Infectious Diseases: How Far Are We?

Drug Repurposing in Antiviral Research: A Current Scenario

Contact Info

Product

Resources

About